Provided by Tiger Trade Technology Pte. Ltd.

Precigen

3.67
-0.2200-5.66%
Post-market: 3.67-0.0048-0.13%19:55 EDT
Volume:7.07M
Turnover:26.54M
Market Cap:1.30B
PE:-2.67
High:4.00
Open:3.80
Low:3.62
Close:3.89
52wk High:5.47
52wk Low:1.11
Shares:353.82M
Float Shares:205.00M
Volume Ratio:0.84
T/O Rate:3.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3727
EPS(LYR):-1.3727
ROE:-571.97%
ROA:-44.30%
PB:62.10
PE(LYR):-2.67

Loading ...

Discover Precigen And 2 Other Insider-Favored Growth Stocks

Simply Wall St.
·
Mar 27

Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday

Benzinga_recent_news
·
Mar 26

Stock Track | ...

Stock Track
·
Mar 26

Precigen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 26

Precigen price target raised to $10 from $9 at H.C. Wainwright

TIPRANKS
·
Mar 26

Stock Track | Precigen Soars 13.87% in Pre-market on First Commercial Sales and Revenue Beat

Stock Track
·
Mar 26

Stock Track | Precigen Soars 16.77% in Night Session on First Commercial Sales and Positive Earnings Report

Stock Track
·
Mar 26

Precigen Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 26

Stocks to Watch: MillerKnoll, Worthington Steel, Navan, Precigen

Dow Jones
·
Mar 26

Precigen Shares Rise on First Drug Sales Report

Dow Jones
·
Mar 26

Stock Track | Precigen Soars 5.16% After-Hours on Revenue Beat and Strong Commercial Momentum for PAPZIMEOS

Stock Track
·
Mar 26

Precigen Q4 EPS $(0.01) Beats $(0.08) Estimate, Sales $4.565M Miss $8.286M Estimate

Benzinga
·
Mar 26

Precigen FY2025 loss per share widens to $1.37; SG&A expenses climb 69.8% to $70 million

Reuters
·
Mar 26

Press Release: Precigen Reports Full Year 2025 Financial Results and Business Updates

Dow Jones
·
Mar 26

Precigen Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Mar 24

Earning Preview: Precigen this quarter’s revenue is expected to increase by 513.75%, and institutional views are bullish

Earnings Agent
·
Mar 18

Precigen to host full-year 2025 results conference call

Reuters
·
Mar 12

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

THOMSON REUTERS
·
Mar 12

Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy?

Simply Wall St.
·
Jan 14

Precigen Highlights PAPZIMEOS Launch Success at J.P. Morgan Healthcare Conference

Reuters
·
Jan 12